The inaugural meeting of the Program on Human Immunology of Cervical Cancers was held at ICGEB New Delhi and marked the beginning of a significant collaborative research initiative.
Held on 6 February 2025, the event brought together prominent experts in the field, with keynote addresses by Dr. Lawrence Banks, Director-General of ICGEB, and Dr. Rafi Ahmad from the Emory Vaccine Center, Atlanta, USA. The joint program between ICGEB and the Emory Vaccine Center aims to understand human immune responses related to HPV control, persistence, and cervical cancer.
Supported by funding from the Bill & Melinda Gates Foundation, this novel research initiative brings together leading global institutions and experts. The program, led by Dr. Rafi Ahmed, harbours collaboration with renowned scientists and clinicians from ICGEB New Delhi, ICGEB Trieste, the ICGEB-Emory Vaccine Program (Dr. Anmol Chandele and Murali Krishna Kaja), the All India Institute of Medical Sciences New Delhi (Dr. Nilanchali Singh), the Emory Winship Cancer Center (Dr. Mihir Patel), Ohio State University (Dr. Andreas Weiland), and the University of Geneva (Dr. Christiane Eberhardt). The initiative is dedicated to advancing the understanding and treatment of cervical cancer through cutting-edge research in human immunology.
Cervical cancer, primarily caused by human papillomaviruses (HPV), remains the fourth most common cancer among women globally. HPV is a diverse group of more than 200 related viruses, classified into low-risk and high-risk types based on their oncogenic potential. While low-risk types cause benign conditions such as genital warts, high-risk types are strongly associated with cervical cancer. While most infections are transient, with up to 90% being spontaneously cleared by the immune system, in a subset of individuals, particularly those with persistent high-risk HPV infections can drive cellular abnormalities, progressing through precancerous stages classified as cervical intraepithelial neoplasia (CIN 1, CIN 2, and CIN 3), with increasing severity. If left unchecked, CIN3 can develop into invasive cervical cancer if these lesions are not detected and treated early.
Millions of women worldwide are infected with high-risk HPV strains, placing them at heightened risk for cervical cancer, a leading cause of cancer-related deaths among women. Routine screening and widespread administration of HPV vaccines can make cervical cancer largely preventable, it remains a major public health burden, particularly in low and middle-income countries (LMICs), where limited access to preventive healthcare, early diagnostic tools, and HPV vaccination leads to disproportionately high incidence and mortality rates. Nearly half of those diagnosed do not survive, emphasizing the urgent need for enhanced prevention and treatment strategies. While current therapies, including surgical resection, chemotherapy, and radiation, can help manage the disease, they often fall short in preventing recurrence, reinforcing the need for novel, targeted interventions to improve long-term patient outcomes.
Understanding why some individuals successfully clear HPV infections, whereas others develop persistent infections, some of which progress to precancerous lesions or cervical cancer, is a critical scientific and clinical challenge. Factors such as immune competence, genetic predisposition, and co-existing infections are believed to play a role, however, the precise mechanisms governing HPV control and persistence remain incompletely understood. Addressing these gaps is essential for improving early detection strategies and developing more effective therapeutic interventions.
A new initiative from the ICGEB-Emory Vaccine Program aims to enhance our understanding of human immune responses to natural HPV infections, with a particular focus on their role in controlling HPV persistence and progression to cervical cancer. This effort seeks to inform strategies for better prevention and intervention by uncovering key immune mechanisms. This research initiative aims to unravel the complexities of the human immune response to HPV, shedding light on the immunological factors determining viral clearance versus persistence. Also, by identifying key immune pathways involved in HPV control and cancer progression, these insights could pave the way for the development of precision immunotherapies tailored to prevent or treat cervical cancer more effectively. Ultimately, this research has the potential to shift the paradigm in cervical cancer prevention and treatment, offering new hope for reducing the global burden of this disease.
